A major goal in retroviral-based gene therapy is to establish methods that allow for the selection and tracking of transduced cell populations. Ex vivo gene marking of normal and malignant hemopoietic cells allows the cells to be followed subsequently in vivo. For in vivo applications, a neutral marker gene that is nonimmunogenic is desirable. To track two distinctively treated cell populations in a single individual, we designed and constructed two retroviral vectors; both of these vectors encode a truncated form of the human low-affinity nerve growth factor receptor, a neutral gene that does not transduce signals and is expected to be nonimmunogenic in humans. The two vectors, named Frape-1 and Frape-3, are identical at the protein level but differ at the DNA level, containing restriction sites that allow easy detection by polymerase chain reaction analysis. We show that cell lines and primary CD34 ϩ cells can be readily transduced with these vectors and that transduced cells can be distinguished by polymerase chain reaction-and vector-specific restriction sites. These vectors will be useful for toxicity studies on in vivo gene therapy and for determining the source of relapse in hematological malignancies. Cancer Gene Therapy (2000) 7, 624 -628
H uman hematopoietic stem cells remain one of the most promising target cells for gene therapeutic approaches to treat malignant and nonmalignant diseases. 1 Retrovirally encoded marker genes have been used to facilitate the detection and selection of retrovirally infected target cells and to follow their fate in vivo. 2 A marker gene needs to fulfill certain requirements, such as easy detection and neutrality in the application used (e.g., should not transduce signals or act as a receptor); for in vivo applications, the marker gene should not be recognized as foreign by the immune system. 3 Several marker genes have been used for retroviral marking studies both in vivo and in vitro. These include the neomycin phosphotransferase gene (neo), 2 the Escherichia coli ␤-galactosidase gene (lacZ), 4, 5 green fluorescent protein, 3, 6 murine CD24, 7 and the low-affinity nerve growth factor receptor (LNGFR). 8, 9 Of these, only LNGFR is of human origin and can therefore be expected to be immunologically neutral and not elicit the generation of cytotoxic T cells, as has been shown to occur for other marker genes. The actual transduced cells will thus be eliminated, precluding analysis of the fate of transduced cells in vivo.
For many studies, it is desirable to have two marker genes that behave identically upon in vivo selection, for instance by encoding the same protein; however, it is also necessary to have the capacity to discriminate between the two by other means. For example, it is not known whether unseparated bone marrow (BM) cells or CD34 ϩ -enriched BM cells result in qualitatively and quantitatively different kinds of reconstitution after transplantation. Similarly, differences in the reconstitution ability of BM stem cells versus peripheral blood stem cells or CD34 ϩ cells versus CD34 ϩ CD38 Ϫ cells are not yet known. With these considerations in mind, we set out to generate a set of retroviral vectors encoding LNGFR but differing from each other and from the endogenous LNGFR gene, so that they could be distinguished by polymerase chain reaction (PCR) analysis.
We show that these vectors transduce CD34 ϩ cells with high efficiency (30 -50%); in addition, they can be distinguished from each other by PCR and restriction digest analysis. These vectors will be used for clinical studies aimed at identifying the source of relapse in autologous stem cell transplantation for hematological malignancies.
MATERIALS AND METHODS

Cells and tissues
Retroviral amphotropic producer lines were generated using the Phoenix amphotropic packaging lines and were cultured in Iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum and antibiotics. All retroviral experiments were conducted in the Shared Retroviral C1 Laboratory at Utrecht University Hospital, in agreement with government guidelines. Jurkat T cells and RPMI 8226 myeloma cells were cultured in RPMI 1640, 10% fetal calf serum, and antibiotics. Normal human BM samples were obtained from healthy individuals who donated BM for transplantation purposes. Informed consent was obtained for the use of a small fraction for research purposes.
Construction of Frape-1 and Frape-3
An 816-bp EagI-BamHI fragment containing the extracellular and transmembrane sequences of LNGFR, except for the first 18 bp, was used as starting material to generate MFG-based retroviral vectors encoding LNGFR. The first 19 bp were cloned into the vector using synthetic oligonucleotides containing different restriction sites but completely coding for the normal amino acid sequence of LNGFR. For Frape-1, we used an oligo CATGGGAGCCGGCGCAACC containing an NcoI site at the start of an NaeI site (not present in wild-type LNGFR; underlined) and an EagI site. For Frape-3, we used an oligo CATGGGCGCCGGTGCCACC containing the same NcoI and EagI sites, but lacking the NaeI site and containing an NarI site (underlined) instead. Using a three-point ligation, a double-stranded oligonucleotide was cloned together with the EagI-BamHI LNGFR fragment into NcoI/BamHI-digested MFG. For Frape-1, we eliminated the 3Ј BamHI site and introduced a new in-frame stop codon. All sequences were confirmed by sequencing the whole insert and part of MFG using an ABI 373 automatic sequencer (Applied Biosystems, Foster City, Calif). Thus, Frape-1 and Frape-3 have amino acid sequences that are identical with those of wild-type LNGFR, but contain novel restriction sites.
Generation of producer lines
Frape-1 and Frape-3 plasmids were cotransfected with a puromycin resistance plasmid at a molar ratio of 1:15 into Phoenix producer cells (kindly provided by Dr. Nolan, Stanford University, Stanford, Calif) using Fugene-6 liposomes (Boehringer Mannheim, Ingelheim, Germany). Cells were selected under 1 g/mL puromycin; in addition, 400 g/mL hygromycin B was used to select for gag/pol expression and 1 mg/mL diphtheria toxin A was used to select for env expression, as described previously. Puromycin-resistant cells were selected for LNGFR expression using a magnetic beads (magneticactivated cell sorting (MACS) system; Miltenyi Biotech, Bergisch-Gladbach, Germany) and an antibody (Ab) against LNGFR (clone 20.4) on MACS. After two rounds of MACS selection, Phoenix cells were Ͼ99% positive for LNGFR.
Retroviral transduction
Cells were transduced using retronectin (Takara Shuzu, Otsu, Japan) -coated 6-cm dishes, in accordance with the procedures described by the manufacturer and by Moritz et al. 10 For Jurkat and RPMI 8226 transductions, 0.5 ϫ 10 6 cells were transduced with 2 mL of viral supernatant that was harvested from 90% confluent producer cells and passed through a 0.22-m filter. Cells were transduced for 24 hours, harvested, and cultured for an additional 3 days. Cells were then stained with Ab against LNGFR, followed by a phycoerythrin (PE)-labeled, isotype-specific, second-step Ab (GaM-IgG-1-PE) and analyzed on a fluorescence-activated cell sorter (FACS). Isotype-matched, Ab-stained cells were used as negative controls.
For transduction of BM CD34 ϩ cells, CD34 MACS-enriched cells were cultured for 1 week in a mixture of thrombopoietin (TPO), stem cell factor (SCF), and Flt-3L, which we have shown elsewhere to be optimal for transduction of CD34 ϩ cells (Y.-Y.N. and F.J.T.S., manuscript submitted for publication). After 1 week, cells were transduced on retronectin-coated plates, harvested, and cultured an additional 1-3 days until analysis on a FACS. 
PCR analysis of transduced cells
RPMI 8226 cells were transduced with Frape-1 or Frape-3, and DNA was extracted using proteinase K and sodium dodecyl sulfate. A total of 10 ng of DNA was used in a PCR to detect Frape-1 or Frape-3. Using one set of primers, both Frape-1 and Frape-3 sequences could be amplified. Forward primer, CTACCAAGAACAACTGGACCGACC; reverse primer, GTTGCAGGCTTTGCAGCACTCACC; PCR conditions, 30 cycles at 95°C for 1 minute, at 60°C for 1 minute, and at 72°C for 1.2 minutes, followed by an additional 5-minute extension at 72°C. The PCR products were digested with NaeI and NarI (the Frape-specific restriction enzymes) and analyzed on a 2% agarose gel. Thus, a different restriction pattern is generated for Frape-1 and Frape-3, allowing discrimination between the two.
RESULTS AND DISCUSSION
Frape-1 and Frape-3 encode the truncated LNGFR gene and differ in the first 19 bp. We originally made a Frape-2 vector by PCR, but this vector contained mutations that did not allow detection by protein surface expression. We used an EagI-BamHI LNGFR fragment and synthetic oligonucleotides, including an NcoI and EagI site, to generate two different 5Ј sites of the gene. Frape-1 has an NaeI site in these 18 bp, and Frape-3 has an NarI site. The 18-bp fragment and the EagI-BamHI LNGFR fragment were cloned into the MFG vector by three-point ligation. In addition, we introduced a small mutation in Frape-1 at the 3Ј end of the coding sequence that eliminates the BamHI site. Both inserts and part of the vector were fully sequenced to confirm the designed features. A schematic design of the vectors is given in Figure 1 .
We transfected these vectors together with a plasmid containing a puromycin resistance gene into the Phoenix amphotropic packaging line. Clones were selected under puromycin and subsequently selected by magnetic beads (MACS) for LNGFR-positive cells. The resulting Frape-1 and Frape-3 producer lines are Ͼ99% positive for LNGFR (data not shown). Supernatant from these cells was used to transduced the Jurkat T-cell line and RPMI 8226 myeloma line on retronectin-coated Petri dishes. Both lines were transduced with high efficiency (Jurkat, 50%; RPMI 8226, 60%), as shown in Figure 2 for Frape-1. Similar results were obtained for Frape-3 (data not shown). Using these cells and a dilution of the supernatant, we determined the titer of Frape-1 to be between 8 ϫ 10 6 and 1 ϫ 10 7 infectious particles per milliliter; the titer of Frape-3 was determined to be between 6 ϫ 10 6 and 8 ϫ 10 6 infectious particles per milliliter (data not shown). We subsequently determined whether CD34 ϩ cells isolated from normal human BM could be efficiently transduced. Using CD34 ϩ -enriched cells and culturing those with TPO, Flt-3 L, and SCF, we obtained transduction efficiencies of ϳ35% of CD34 ϩ cells (Fig 3) . This shows that the Frape vectors can be used for stem cell transplantation applications. To determine whether Frape-1-and Frape-3-transduced cells could indeed be distinguished from each other, we transduced RPMI 8226 myeloma cells with Frape-1 and Frape-3 and extracted DNA from these cells. Using primers specific for both Frape-1 and Frape-3, we were able to amplify specific bands of the expected size from both Frape-1 and Frape-3 transduced in one PCR. The PCR products were able to be identified as specific for Frape-1 or Frape-3 using the restriction sites introduced in Frape-1 (NaeI) and Frape-3 (NarI), as shown in Figure 4 . The use of restriction enzyme differences ensures that the differences in the detection of Frape-1 or Frape-3 are not caused by differences in the efficiency of the PCR, but reflect true expression differences between transduced populations. Thus, Frape-1-and Frape-3-transduced cells can be identified at the protein level with the same monoclonal Ab; however, they can be readily distinguished from each other using PCR analysis with one set of primers followed by vector-specific restriction digest.
In summary, we describe a set of retroviral vectors that are identical at the protein level but differ at the DNA level, containing restriction sites that allow easy detection by PCR analysis. We show that cell lines and primary CD34 ϩ cells can be readily transduced with these vectors, and that transduced cells can be distinguished by vectorspecific PCR. We anticipate three possible applications for these vectors. First, they will be useful for toxicity studies on in vivo gene therapy. Second, they allow estimation of the contribution to reconstitution from two different stem cell sources. Third, they may help in determining source of relapse in hematological malignancies. For this latter application, these vectors will be used in a study sponsored by the European Union and conducted by a European consortium of groups from Sweden, Italy, the United Kingdom, and The Netherlands. These vectors may also be useful for other clinical applications, such as those mentioned above.
